CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 185.64 AUD 1.04% Market Closed
Market Cap: 90.1B AUD

CSL Ltd
Interest Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

CSL Ltd
Interest Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Expense CAGR 3Y CAGR 5Y CAGR 10Y
CSL Ltd
ASX:CSL
Interest Expense
$444m
CAGR 3-Years
36%
CAGR 5-Years
26%
CAGR 10-Years
22%
Opthea Ltd
ASX:OPT
Interest Expense
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mesoblast Ltd
ASX:MSB
Interest Expense
$21.8m
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Interest Expense
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Interest Expense
AU$4.8m
CAGR 3-Years
239%
CAGR 5-Years
110%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Interest Expense
AU$62.2k
CAGR 3-Years
24%
CAGR 5-Years
8%
CAGR 10-Years
N/A
No Stocks Found

CSL Ltd
Glance View

In the bustling world of biotech innovation, CSL Limited stands as a stalwart, renowned for not just navigating but shaping the industry's intricate landscape. Founded in 1916, this Australian giant has grown from its humble beginnings to become a global leader in the biopharmaceutical sector. CSL operates primarily through two main segments: CSL Behring and Seqirus. CSL Behring is the cornerstone of the company's growth, specializing in the development of life-saving therapies derived from human plasma. These therapies are pivotal in treating rare and serious diseases such as hemophilia, immune deficiencies, and hereditary angioedema. The company has built an impressive collection of facilities across several continents, focusing on plasma collection and processing, which underscores its commitment to advanced therapeutic solutions. Alongside CSL Behring, Seqirus has emerged as a formidable force in the influenza vaccine market and is now one of the world's largest flu vaccine providers. The acquisition and transformation of this division signify CSL’s strategic expansion into broader preventive healthcare. From developing and distributing advanced technologies in cell-based and adjuvanted influenza vaccines to advancing research in universal flu vaccines, Seqirus exemplifies CSL's innovative spirit. Collectively, these divisions illustrate how CSL marries cutting-edge research with robust global operations to generate robust revenues, addressing pressing healthcare needs across the globe while promising new horizons in medical science.

CSL Intrinsic Value
228.69 AUD
Undervaluation 19%
Intrinsic Value
Price

See Also

What is CSL Ltd's Interest Expense?
Interest Expense
444m USD

Based on the financial report for Jun 30, 2025, CSL Ltd's Interest Expense amounts to 444m USD.

What is CSL Ltd's Interest Expense growth rate?
Interest Expense CAGR 10Y
22%

Over the last year, the Interest Expense growth was -7%. The average annual Interest Expense growth rates for CSL Ltd have been 36% over the past three years , 26% over the past five years , and 22% over the past ten years .

Back to Top